Ironwood Pharmaceuticals Given New $10.00 Price Target at Wedbush (IRWD)
Stock analysts at Wedbush lowered their target price on shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from $12.00 to $10.00 in a report issued on Wednesday, American Banking News reports. The firm currently has a “neutral” rating on the stock. Wedbush’s target price suggests a potential downside of 0.30% from the company’s current price.
Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at 10.03 on Wednesday. Ironwood Pharmaceuticals has a 1-year low of $9.83 and a 1-year high of $19.67. The stock has a 50-day moving average of $11.89 and a 200-day moving average of $13.81. The company’s market cap is $1.138 billion.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Tuesday, October 22nd. The company reported ($0.51) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.57) by $0.06. The company had revenue of $4.90 million for the quarter, compared to the consensus estimate of $6.54 million. During the same quarter in the prior year, the company posted $0.42 earnings per share. The company’s quarterly revenue was down 94.9% on a year-over-year basis. On average, analysts predict that Ironwood Pharmaceuticals will post $-2.44 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on IRWD. Analysts at Cantor Fitzgerald cut their price target on shares of Ironwood Pharmaceuticals from $10.00 to $9.00 in a research note to investors on Wednesday. They now have a “hold” rating on the stock. Separately, analysts at Zacks reiterated an “outperform” rating on shares of Ironwood Pharmaceuticals in a research note to investors on Wednesday, October 16th. They now have a $13.00 price target on the stock. Finally, analysts at UBS AG cut their price target on shares of Ironwood Pharmaceuticals from $10.50 to $9.00 in a research note to investors on Tuesday, October 15th. They now have a “sell” rating on the stock. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the stock. Ironwood Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $13.59.
Ironwood Pharmaceuticals, Inc is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.